Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference
August 29 2018 - 7:30AM
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company
focused on the development and commercialization of novel medicines
to treat liver disease, today announced that it has been invited to
present at the BioCentury 25th Annual NewsMakers in the Biotech
Industry Conference on Friday, September 7, 2018, in New York.
Steven Mento, Ph.D., President and Chief Executive Officer of
Conatus, is scheduled to present a corporate overview and business
update at 10:30 a.m. ET. A webcast of the presentation will be
available live and archived in the Investors section of the
company’s website at www.conatus.com.
Host BioCentury handpicks only 48 companies to present their
stories to biotech sector institutional investors. At the
NewsMakers conference held in 2017, more than 500 delegates
congregated at NewsMakers, including money managers who controlled
more than $600 billion in equity assets, with over $50 billion
dedicated to healthcare and $15 billion dedicated to biotech.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease. In
collaboration with Novartis, Conatus is developing its lead
compound, emricasan, for the treatment of patients with chronic
liver disease. Emricasan is a first-in-class, orally active
pan-caspase inhibitor designed to reduce the activity of enzymes
that mediate inflammation and apoptosis. Conatus believes that by
reducing the activity of these enzymes, caspase inhibitors have the
potential to interrupt the progression of a variety of diseases.
For additional information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward looking statements, including
statements regarding: caspase inhibitors' potential to
interrupt the progression of a variety of diseases. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other similar expressions. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions, including those risks described in the company’s prior
press releases and in the periodic reports it files with the
Securities and Exchange Commission. The events and
circumstances reflected in the company’s forward-looking statements
may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements.
Except as required by applicable law, the company does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
CONTACT: Alan EngbringConatus
Pharmaceuticals Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024